Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9013328 | 0.83 | OPRM1 (0.42) | ALDH1A1OPRM1OPRL1SIGMAR1 | |
| SCHEMBL9013676 | 0.83 | SIGMAR1 (0.44) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL9013280 | 0.82 | KCNH2 (0.43) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL9013618 | 0.82 | KCNH2 (0.43) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL9013715 | 0.82 | KCNH2 (0.43) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL9013460 | 0.82 | KCNH2 (0.43) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL25401977 | 0.81 | DPP4 (0.44) | ALDH1A1SIGMAR1KDM1AMAOAMAOB | |
| SCHEMBL13545892 | 0.81 | ALDH1A1 (0.55) | ALDH1A1OPRM1OPRL1CRHBPCRHR2 | |
| SCHEMBL18114517 | 0.81 | MAOA (0.45) | ALDH1A1OPRM1OPRL1GAAMAOA | |
| SCHEMBL16029497 | 0.79 | MAOA (0.47) | ALDH1A1OPRM1OPRL1GAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113387916-A | Urolithin PDE2 inhibitor compound and preparation method thereof | 常州大学 | 2021-09-14 | — | — | CN | claimed |
| EP-3274318-B1 | PRODUCTION OF BIPHENYL COMPOUNDS | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2020-02-26 | — | — | EP | claimed |
| EP-3274318-A1 | PRODUCTION OF BIPHENYL COMPOUNDS | ExxonMobil Chemical Patents Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| US-20160280616-A1 | Production of Biphenyl Compounds | EXXONMOBIL CHEMICAL PATENTS INC. | 2016-09-29 | — | — | US | claimed |
| WO-2016153575-A1 | PRODUCTION OF BIPHENYL COMPOUNDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280616-A1 | Production of Biphenyl Compounds | AHR, ARNT, CYP1B1 | ALDH1A1 474/4885OPRM1 2260/4885OPRL1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.